Published online Nov 25, 2015. doi: 10.4239/wjd.v6.i16.1309
Peer-review started: July 13, 2015
First decision: August 19, 2015
Revised: September 3, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 25, 2015
Processing time: 138 Days and 3.8 Hours
Since the discovery of therapeutic insulin in 1922 and the development of the non-obese diabetic spontaneous mouse model in 1980, the establishment of Network for the Pancreatic Organ Donor with Diabetes (nPOD) in 2007 is arguably the most important milestone step in advancing type 1 diabetes (T1D) research. In this perspective, we briefly describe how nPOD is transforming T1D research via procuring and coordinating analysis of disease pathogenesis directly in human organs donated by deceased diabetic and control subjects. The successful precedent set up by nPOD is likely to spread far beyond the confines of research in T1D to revolutionize biomedical research of other disease using high quality procured human cells and tissues.
Core tip: Type 1 diabetes (T1D) strikes early in life with monumental impact on life style and long term health of affected children. There is currently no cure for T1D or mechanisms to protect at risk individuals. A major obstacle is the difficulty in translating the interventions that succeeded in preventing or reversing the disease in the non-obese diabetic mouse model into human immunotherapies. Network for the Pancreatic Organ Donor with Diabetes has been established in 2007 to study the disease directly in humans by procuring and offering well preserved tissues to investigators. These efforts, as indicated by published results, are paying off by providing critical new insights that are expected to facilitate development of efficacious immunotherapies.